| dc.contributor.author | Lucas Otieno, Yolanda Guerra Mendoza, Samuel Adjei, Tsiri Agbenyega, Selidji Todagbe Agnandji, Pedro Aide, Pauline Akoo, Daniel Ansong, Kwaku Poku Asante, James A Berkley, Samwel Gesase, Mary J Hamel, Irving Hoffman, Seyram Kaali, Portia Kamthunzi, Simon Kariuki, Peter Kremsner, Miguel Lanaspa, Bertrand Lell, Marc Lievens, John Lusingu, Anangisye Malabeja, Nahya Salim Masoud, Ali Takadir Mtoro, Patricia Njuguna, Opokua Ofori-Anyinam, Godfrey Allan Otieno, Walter Otieno, Seth Owusu-Agyei, Lode Schuerman, Hermann Sorgho, Marcel Tanner, Halidou Tinto, Innocent Valea, Pascale Vandoolaeghe, Jahit Sacarlal, Martina Oneko | |
| dc.description.abstract | We assessed the safety and immunogenicity of the RTS,S/AS01 malaria vaccine in a subset of children identified as HIV-infected during a large phase III randomized controlled trial conducted in seven sub-Saharan African countries.
Methods
Infants 6–12 weeks and children 5–17 months old were randomized to receive 4 RTS,S/AS01 doses (R3R group), 3 RTS,S/AS01 doses plus 1 comparator vaccine dose (R3C group), or 4 comparator vaccine doses (C3C group) at study months 0, 1, 2 and 20. Infants and children with WHO stage III/IV HIV disease were excluded but HIV testing was not routinely performed on all participants; our analyses included children identified as HIV-infected based on medical history or clinical suspicion and confirmed by polymerase chain reaction or antibody testing. Serious adverse events (SAEs) and anti-circumsporozoite (CS) antibodies were assessed.
Results | en_US |
